Literature DB >> 16758257

Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population.

Marja K Pasanen1, Janne T Backman, Pertti J Neuvonen, Mikko Niemi.   

Abstract

OBJECTIVE: Organic anion transporting polypeptide 1B1 (OATP1B1) is a drug uptake transporter located at the sinusoidal membrane of hepatocytes. Our aim was to establish high-throughput genotyping assays for the major known single nucleotide polymorphisms (SNP) in the SLCO1B1 gene encoding OATP1B1 and to investigate the frequencies of SNPs and haplotypes of SLCO1B1 in a large Caucasian population.
METHODS: Distribution of SLCO1B1 alleles was determined in 468 healthy Finnish Caucasian subjects at 11 variant sites spanning the entire gene by using allelic discrimination with TaqMan 5' nuclease assays.
RESULTS: The allelic frequencies of SLCO1B1 SNPs were 9.7% for g.-11187G>A, 0.4% for g.-11110T>G, 8.0% for g.-10499A>C, 46.2% for c.388A>G, 13.1% for c.411G>A, 13.1% for c.463C>A, 20.2% for c.521T>C, 53.2% for c.571T>C, 46.4% for c.597C>T, 4.0% for c.1929A>C and 48.8% for c.*439T>G. Altogether, 26 haplotypes were statistically inferred. The most common haplotype, with a frequency of 35.6%, contained variant allele C at position c.571, but had the reference nucleotide at all other positions investigated. The functionally significant c.521T>C SNP existed in four major haplotypes, which could be differentiated by the g.-11187G>A, g.-10499A>C and c.388A>G SNPs. The frequencies of these haplotypes were 7.9% for g.-11187G/g.-10499C/c.388G/c.521C (*16), 6.9% for AAGC (*17), 2.7% for GAAC (*5) and 2.4% for GAGC (*15).
CONCLUSION: Sequence variations of SLCO1B1 occur at high frequencies in the Caucasian population. Further studies are needed to characterise the effects of SLCO1B1 haplotypes, especially *16, *17, *15 and *5, on drug pharmacokinetics and response, and to determine the frequencies of SLCO1B1 SNPs and haplotypes in different populations.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16758257     DOI: 10.1007/s00228-006-0123-1

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  26 in total

1.  Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes.

Authors:  D Nakai; R Nakagomi; Y Furuta; T Tokui; T Abe; T Ikeda; K Nishimura
Journal:  J Pharmacol Exp Ther       Date:  2001-06       Impact factor: 4.030

2.  A comparison of bayesian methods for haplotype reconstruction from population genotype data.

Authors:  Matthew Stephens; Peter Donnelly
Journal:  Am J Hum Genet       Date:  2003-10-20       Impact factor: 11.025

3.  Influence of common variants in the pharmacokinetic genes (OATP-C, UGT1A1, and MRP2) on serum bilirubin levels in healthy subjects.

Authors:  Ichiro Ieiri; Hiroshi Suzuki; Miyuki Kimura; Hiroshi Takane; Yohei Nishizato; Shin Irie; Akinori Urae; Kiyoshi Kawabata; Shun Higuchi; Kenji Otsubo; Yuichi Sugiyama
Journal:  Hepatol Res       Date:  2004-10       Impact factor: 4.288

Review 4.  Transporters and drug therapy: implications for drug disposition and disease.

Authors:  Richard H Ho; Richard B Kim
Journal:  Clin Pharmacol Ther       Date:  2005-09       Impact factor: 6.875

5.  Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17.

Authors:  Mikko Niemi; Pertti J Neuvonen; Ute Hofmann; Janne T Backman; Matthias Schwab; Dieter Lütjohann; Klaus von Bergmann; Michel Eichelbaum; Kari T Kivistö
Journal:  Pharmacogenet Genomics       Date:  2005-05       Impact factor: 2.089

6.  Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1).

Authors:  Mikko Niemi; Kari T Kivistö; Ute Hofmann; Matthias Schwab; Michel Eichelbaum; Martin F Fromm
Journal:  Br J Clin Pharmacol       Date:  2005-05       Impact factor: 4.335

7.  Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers.

Authors:  Jae-Yong Chung; Joo-Youn Cho; Kyung-Sang Yu; Jung-Ryul Kim; Dal-Seok Oh; Hye-Ryung Jung; Kyoung-Soo Lim; Ki-Ho Moon; Sang-Goo Shin; In-Jin Jang
Journal:  Clin Pharmacol Ther       Date:  2005-10       Impact factor: 6.875

8.  Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells.

Authors:  Yoshio Kameyama; Keiko Yamashita; Kaoru Kobayashi; Masakiyo Hosokawa; Kan Chiba
Journal:  Pharmacogenet Genomics       Date:  2005-07       Impact factor: 2.089

9.  A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters.

Authors:  B Hsiang; Y Zhu; Z Wang; Y Wu; V Sasseville; W P Yang; T G Kirchgessner
Journal:  J Biol Chem       Date:  1999-12-24       Impact factor: 5.157

10.  Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics.

Authors:  Yohei Nishizato; Ichiro Ieiri; Hiroshi Suzuki; Miyuki Kimura; Kiyoshi Kawabata; Takeshi Hirota; Hiroshi Takane; Shin Irie; Hiroyuki Kusuhara; Yoko Urasaki; Akinori Urae; Shun Higuchi; Kenji Otsubo; Yuichi Sugiyama
Journal:  Clin Pharmacol Ther       Date:  2003-06       Impact factor: 6.875

View more
  33 in total

1.  Frequency of the SLCO1B1 388A>G and the 521T>C polymorphism in Tanzania genotyped by a new LightCycler®-based method.

Authors:  Eleni Aklillu; Sabina Mugusi; Eliford Ngaimisi; Michael Marcus Hoffmann; Sonja König; Victoria Ziesenitz; Gerd Mikus; Walter Emil Haefeli; Johanna Weiss
Journal:  Eur J Clin Pharmacol       Date:  2011-06-01       Impact factor: 2.953

Review 2.  Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans.

Authors:  Kari T Kivistö; Mikko Niemi
Journal:  Pharm Res       Date:  2006-12-20       Impact factor: 4.200

3.  No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin.

Authors:  Jenni E Keskitalo; Kaisa J Kurkinen; Mikko Neuvonen; Janne T Backman; Pertti J Neuvonen; Mikko Niemi
Journal:  Br J Clin Pharmacol       Date:  2009-08       Impact factor: 4.335

Review 4.  Mechanisms and assessment of statin-related muscular adverse effects.

Authors:  Dirk Moßhammer; Elke Schaeffeler; Matthias Schwab; Klaus Mörike
Journal:  Br J Clin Pharmacol       Date:  2014-09       Impact factor: 4.335

5.  Functional Consequences of Pravastatin Isomerization on OATP1B1-Mediated Transport.

Authors:  Jonathan B Wagner; Melissa Ruggiero; J Steven Leeder; Bruno Hagenbuch
Journal:  Drug Metab Dispos       Date:  2020-09-05       Impact factor: 3.922

6.  Brazilian cohort and genes encoding for drug-metabolizing enzymes and drug transporters.

Authors:  Vera Kim; Thijs van der Wal; Miriam Yumie Nishi; Luciana Ribeiro Montenegro; Flair Jose Carrilho; Yujin Hoshida; Suzane Kioko Ono
Journal:  Pharmacogenomics       Date:  2020-06-03       Impact factor: 2.533

7.  Non-synonymous polymorphisms in the human SLCO1B1 gene: an in vitro analysis of SNP c.1929A>C.

Authors:  Annick Seithel; Kathrin Klein; Ulrich M Zanger; Martin F Fromm; Jörg König
Journal:  Mol Genet Genomics       Date:  2007-11-08       Impact factor: 3.291

8.  PharmGKB very important pharmacogene: SLCO1B1.

Authors:  Connie Oshiro; Lara Mangravite; Teri Klein; Russ Altman
Journal:  Pharmacogenet Genomics       Date:  2010-03       Impact factor: 2.089

9.  The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range.

Authors:  Annikka Kalliokoski; Mikko Neuvonen; Pertti J Neuvonen; Mikko Niemi
Journal:  Br J Clin Pharmacol       Date:  2008-09-23       Impact factor: 4.335

Review 10.  Impact of OATP transporters on pharmacokinetics.

Authors:  A Kalliokoski; M Niemi
Journal:  Br J Pharmacol       Date:  2009-09-25       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.